Jain Rita — SEC insider filings

SEC reporting owner CIK 1707797. 34 insider filings on record with FilingPulse; latest filed 2026-10-02.

Transaction summary — filings shown

Covers all 34 filings on record, filed 2021-01-25 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
ChemoCentryx, Inc. (CCXI)EVP, Chief Medical Officer, Director7——21
ANAPTYSBIO, INC (ANAB)Director6——16
First Tracks Biotherapeutics, Inc. (TRAX)Director4——15
Avalo Therapeutics, Inc. (AVTX)Director7——7
Immunovant, Inc. (IMVT)Chief Medical Officer3——7
Celldex Therapeutics, Inc. (CLDX)Director4——4
Provention Bio, Inc. (PRVB)Director2——2
SAB Biotherapeutics, Inc. (SABS)Director1——1

Insider filings — Jain Rita

FiledFormIssuerReported transactionsSource
2026-10-024Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 1,322 (derivative) @ $12.29EDGAR
2026-07-024Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 1,080 (derivative) @ $15.04EDGAR
2026-06-294Celldex Therapeutics, Inc. (CLDX)Grant/award (A): 26,000 (derivative) @ $0EDGAR
2026-06-174First Tracks Biotherapeutics, Inc. (TRAX)Option exercise (M): 7,330 @ $0 · Option exercise (M): 6,030 (derivative) @ $0 · Option exercise (M): 1,300 (derivative) @ $0EDGAR
2026-06-124/AFirst Tracks Biotherapeutics, Inc. (TRAX)Grant/award (A): 2,500 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2026-06-044Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 20,100 (derivative) @ $0EDGAR
2026-05-144First Tracks Biotherapeutics, Inc. (TRAX)Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 42,000 (derivative) @ $0EDGAR
2026-04-224First Tracks Biotherapeutics, Inc. (TRAX)Grant/award (A): 10,600 (derivative) @ $0 · Grant/award (A): 8,015 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 1,300 (derivative) @ $0 · +2 moreEDGAR
2026-04-014Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 1,339 (derivative) @ $12.13EDGAR
2026-01-084ANAPTYSBIO, INC (ANAB)Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0EDGAR
2026-01-074SAB Biotherapeutics, Inc. (SABS)Grant/award (A): 240,000 (derivative) @ $0EDGAR
2026-01-054Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 1,043 (derivative) @ $14.74EDGAR
2025-10-024Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 1,572 (derivative) @ $0EDGAR
2025-06-184Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 40,200 (derivative) @ $0EDGAR
2025-06-174ANAPTYSBIO, INC (ANAB)Option exercise (M): 7,330 @ $0 · Option exercise (M): 1,300 (derivative) @ $0 · Option exercise (M): 6,030 (derivative) @ $0EDGAR
2025-06-094Celldex Therapeutics, Inc. (CLDX)Grant/award (A): 16,500 (derivative) @ $0EDGAR
2025-01-074ANAPTYSBIO, INC (ANAB)Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 6,030 (derivative) @ $0EDGAR
2024-06-184ANAPTYSBIO, INC (ANAB)Option exercise (M): 4,534 @ $0 · Option exercise (M): 3,234 (derivative) @ $0 · Option exercise (M): 1,300 (derivative) @ $0EDGAR
2024-06-174Celldex Therapeutics, Inc. (CLDX)Grant/award (A): 16,500 (derivative) @ $0EDGAR
2024-01-054ANAPTYSBIO, INC (ANAB)Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 6,030 (derivative) @ $0EDGAR
2023-04-274Provention Bio, Inc. (PRVB)Disposition to issuer (D): 66,000 (derivative)EDGAR
2023-04-064ANAPTYSBIO, INC (ANAB)Grant/award (A): 10,600 (derivative) @ $0 · Grant/award (A): 8,015 (derivative) @ $0 · Grant/award (A): 3,900 (derivative) @ $0 · Grant/award (A): 3,234 (derivative) @ $0EDGAR
2023-02-214Celldex Therapeutics, Inc. (CLDX)Grant/award (A): 17,100 (derivative) @ $0EDGAR
2023-01-054Provention Bio, Inc. (PRVB)Grant/award (A): 66,000 (derivative) @ $0EDGAR
2022-10-244ChemoCentryx, Inc. (CCXI)Disposition to issuer (D): 35,863 · Disposition to issuer (D): 307 (derivative) · Disposition to issuer (D): 14,393 (derivative) · Disposition to issuer (D): 21,052 (derivative) · Disposition to issuer (D): 23,948 (derivative) · Disposition to issuer (D): 4,504 (derivative) · +2 moreEDGAR
2022-05-244ChemoCentryx, Inc. (CCXI)Option exercise (M): 7,726 @ $0 · Option exercise (M): 7,726 (derivative)EDGAR
2022-03-294ChemoCentryx, Inc. (CCXI)Option exercise (M): 5,251 @ $0 · Option exercise (M): 5,251 (derivative)EDGAR
2022-02-244ChemoCentryx, Inc. (CCXI)Grant/award (A): 11,600 (derivative) · Grant/award (A): 14,700 (derivative)EDGAR
2021-10-074ChemoCentryx, Inc. (CCXI)Grant/award (A): 45,000 (derivative)EDGAR
2021-05-244ChemoCentryx, Inc. (CCXI)Option exercise (M): 4,660 @ $0 · Grant/award (A): 7,726 (derivative) · Grant/award (A): 4,504 (derivative) · Option exercise (M): 4,660 (derivative)EDGAR
2021-03-314/AImmunovant, Inc. (IMVT)Grant/award (A): 97,600 @ $0 · Grant/award (A): 11,765 @ $0 · Grant/award (A): 342,300 (derivative) @ $0EDGAR
2021-03-304ChemoCentryx, Inc. (CCXI)Option exercise (M): 5,251 @ $0 · Option exercise (M): 5,251 (derivative)EDGAR
2021-03-234Immunovant, Inc. (IMVT)Grant/award (A): 109,365 @ $0 · Grant/award (A): 342,300 (derivative) @ $0EDGAR
2021-01-254Immunovant, Inc. (IMVT)Grant/award (A): 20,000 @ $0 · Grant/award (A): 220,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-01-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1707797 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs